Latest News
Sartorius to Acquire Select Danaher Life Science Businesses for USD 750m
Tuesday 22 October 2019

22 October 2019 - Germany based biopharmaceutical partner Sartorius has agreed to acquire parts of the life science portfolio of Washington, DC-based conglomerate Danaher for approximately USD 750m in cash, the company said.
The proposed transaction is expected to be completed in the first quarter of 2020 and is subject to customary closing conditions and the successful acquisition of the GE Biopharma business by Danaher.
The portfolio proposed to be acquired includes three businesses that are currently part of Danaher's Life Science platform:
The label-free biomolecular characterisation business (FortéBio) comprises innovative protein analysis instruments, biosensors and reagents that are used in drug discovery and would become part of Sartorius' bioanalytics unit within its Lab Products and Services division.
With the chromatography hardware and resins business, Sartorius would expand the offerings of its Bioprocess Solutions division.
The third business, SoloHill, includes mainly a microcarrier technology and particle validation standards used in cell culture and other bioprocesses.
This proposed transaction, Danaher's acquisition of the GE Biopharma business, the proposed regulatory remedies (the package of assets being sold) for Danaher's acquisition of the GE Biopharma business, and Sartorius as the buyer in such remedies, are all subject to approvals from various regulatory authorities.
The Sartorius Group is an international partner of biopharmaceutical research and the industry.
With innovative laboratory instruments and consumables, the Group's Lab Products and Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently.
Danaher's life science businesses had combined sales turnover of approximately USD 140m in 2018 with a strong growth profile and double-digit profit margins. Danaher operates in four segments: environmental and applied solutions, life sciences, diagnostics and dental.
Details
Date Published: 22/10/2019
Target: Danaher/ parts of life science portfolio
Country: USA
Deal Size: 750m (USD)
Sector: Pharmaceuticals
Type: Corporate acquisition
Financing: Cash
Status: Agreed
Vendor: Danaher
Buyer: Sartorius
Comment:


Options